Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Beclomethasone Dipropionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 6/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.95 |
| ▸ | USP2 | O75604 | 6/20 | 0.95 |
| ▸ | PGR | P06401 | 5/20 | 0.95 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.95 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.95 |
| ▸ | AR | P10275 | 2/20 | 0.95 |
| ▸ | CNR1 | P21554 | 2/20 | 0.95 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.95 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.95 |
| ▸ | MAPT | P10636 | 3/20 | 0.77 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.77 |
| ▸ | DRD2 | P14416 | 1/20 | 0.77 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 5/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 4/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | MLNR | O43193 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Beclomethasone Dipropionate SCHEMBL7329 | 1.00 | CYP3A4 (0.95) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL74651 | 0.99 | CYP3A4 (0.94) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL3930413 | 0.98 | CYP3A4 (0.91) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL10392062 | 0.98 | CYP3A4 (1.00) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL19681908 | 0.98 | CYP3A4 (1.00) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL6941956 | 0.98 | CYP3A4 (1.00) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL13653326 | 0.98 | CYP3A4 (1.00) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL9768491 | 0.98 | CYP3A4 (1.00) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL6890 | 0.98 | CYP3A4 (1.00) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL2404673 | 0.98 | CYP3A4 (1.00) | CYP3A4USP2NR3C1PGRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859550-B2 | Heterocyclic inhibitors of histamine receptors for the treatment of disease | KALYPSYS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20130245001-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2013039785-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245001-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH2, HRH3 | NR3C1 396/4885CYP3A4 775/4885USP2 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.